1. Home
  2. ELTX vs ONCY Comparison

ELTX vs ONCY Comparison

Compare ELTX & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$10.71

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

HOLD

Current Price

$0.85

Market Cap

112.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
ONCY
Founded
2011
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.4M
112.5M
IPO Year
2014
2002

Fundamental Metrics

Financial Performance
Metric
ELTX
ONCY
Price
$10.71
$0.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$18.00
$7.33
AVG Volume (30 Days)
132.9K
1.1M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
39.29
N/A
EPS
N/A
N/A
Revenue
$2,301,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2,505.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.80
$0.33
52 Week High
$14.93
$1.51

Technical Indicators

Market Signals
Indicator
ELTX
ONCY
Relative Strength Index (RSI) 47.92 38.50
Support Level $9.97 $0.80
Resistance Level $11.47 $1.18
Average True Range (ATR) 0.87 0.06
MACD -0.01 -0.01
Stochastic Oscillator 28.81 8.07

Price Performance

Historical Comparison
ELTX
ONCY

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Share on Social Networks: